Tag: Bureau of Competition

Displaying 321 - 340 of 384 results.

The Federal Trade Commission today filed a motion in U.S. District Court for the District of Columbia, pursuant to Section 7A(g)(2) of the Clayton Act, 15 U.S.C. § 18a(g)(2), to require Blockbuster, Inc. to comply with the statutory rules of the Hart-Scott-Rodino Act (HSR).
The Federal Trade Commission today announced that it will conditionally allow Genzyme Corporation’s (Genzyme) proposed $1 billion acquisition of ILEX Oncology, Inc. (Ilex), provided the companies divest overlapping assets in the U.S. market for solid organ transplant (SOT) acute therapy drugs....
By a 3-1-1 vote, the Federal Trade Commission today closed its investigation into Genzyme Corporation's (Genzyme) 2001 acquisition of Novazyme Pharmaceuticals, Inc. (Novazyme). At the time of its acquisition, Novazyme was engaged primarily in conducting early pre-clinical studies relating to...
The Federal Trade Commission has issued a unanimous policy statement on the use of monetary equitable remedies such as disgorgement and restitution in competition cases – specifically, those involving violations of the Hart-Scott-Rodino (HSR) Premerger Notification Act, the FTC Act, and the...
Presenting keynote remarks at an annual conference on "Current Topics in Merger and Antitrust Enforcement" in Washington, DC, today Federal Trade Commission Competition Director Joe Simons announced the Bureau's new "Guidelines for Merger Investigations," which are designed to incorporate recently...
The Federal Trade Commission today released the materials relating to the workshop on Health Care Competition Law and Policy, held on September 9-10, 2002. The workshop focused on the implications of competition law and policy for health care financing and delivery and considered the impact of...

Pages